Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| P50-09262-1 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Texas | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate dextroamphetamine sulfate (sustained release) as an adjunct in cocaine treatment; an evaluation of the ""replacement"" strategy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | 15/30 mg d-amphetamine |
|
| 2 | Experimental | 30/60 mg d-amphetamine |
|
| 3 | Experimental | placebo |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dextroamphetamine | Drug | 15 mg for first 8 weeks and 30 mg for 2nd 8 weeks |
| |
| Measure | Description | Time Frame |
|---|---|---|
| verifiable cocaine abstinence | 16 weeks of study |
Not provided
Not provided
Please contact site for information.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| John Grabowski, Ph.D. | University of Texas | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Texas Health Science Center | Houston | Texas | 77225 | United States |
Not provided
| ID | Term |
|---|---|
| D019970 | Cocaine-Related Disorders |
| D019966 | Substance-Related Disorders |
| ID | Term |
|---|---|
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D003913 | Dextroamphetamine |
| ID | Term |
|---|---|
| D000661 | Amphetamine |
| D000662 | Amphetamines |
| D010627 | Phenethylamines |
| D005021 | Ethylamines |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D-Amphetamine |
| Drug |
30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total) |
|
| Placebo | Drug | Placebo |
|
| D000588 |
| Amines |
| D009930 | Organic Chemicals |